Insulin analogues and cancer risk: the emergence of second-generation studies.
AuthorsRenehan, Andrew G
AffiliationSchool of Cancer and Enabling Sciences, University of Manchester, Manchester Academic Health Science Centre, The Christie NHS Foundation Trust, Wilmslow Road, Manchester, M20 4BX, UK. firstname.lastname@example.org
MetadataShow full item record
AbstractA number of observational studies have linked insulin glargine (A21Gly,B31Arg,B32Arg human insulin) with a putative increased cancer risk, particularly breast cancer, but many of these 'first generation' studies had study design and analysis flaws, and were inconclusive. A small number of 'second generation' studies are now emerging in which the applied pharmaco-epidemiological principles are more robust. For example, when Ruitar and colleagues (Diabetologia DOI: 10.1007/s00125-011-2312-4 ) focused specifically on breast cancer rather than all incident cancer risk, they were able to show a positive association with insulin glargine for breast cancer although there was no association with all incident cancer risk. A list of preferred qualities for pharmaco-epidemiological studies is presented.
CitationInsulin analogues and cancer risk: the emergence of second-generation studies. 2012, 55 (1):7-9 Diabetologia
- Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study.
- Authors: Ruiter R, Visser LE, van Herk-Sukel MP, Coebergh JW, Haak HR, Geelhoed-Duijvestijn PH, Straus SM, Herings RM, Stricker BH
- Issue date: 2012 Jan
- Risk of breast cancer in patients on long-acting insulin analogues in comparison with those on human insulin.
- Authors: Kostev K
- Issue date: 2012 May
- Insulin glargine and risk of cancer: a cohort study in the French National Healthcare Insurance Database.
- Authors: Blin P, Lassalle R, Dureau-Pournin C, Ambrosino B, Bernard MA, Abouelfath A, Gin H, Le Jeunne C, Pariente A, Droz C, Moore N
- Issue date: 2012 Mar
- Long-term effects of insulin glargine on the risk of breast cancer.
- Authors: Suissa S, Azoulay L, Dell'Aniello S, Evans M, Vora J, Pollak M
- Issue date: 2011 Sep